ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brexpiprazole

Also written as “Brexpiprazole”, “OPC-34712” and “Brexpiprazole (OPC-34712)”.

Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Stress Disorders, Post-Traumatic · Alzheimer Disease · Mania, led by 3 companies.

Drug pageBrexpiprazole: every studyAll 79 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 29, 202170 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only600 open or runningphase 4since Mar 29, 2021Nov 24, 2008none ahead
H. Lundbeckits history only90 open or runningphase 3since Mar 11, 2013Mar 11, 2013none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Dec 4, 2025Dec 4, 2025none ahead

Also a collaborator on its studies: Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Humanis Saglık Anonim Sirketi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 4, 2025First study: phase 1 study in SchizophreniaFirst studyNCT07266792 · 36 enrolled · India

TargetBeta

“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131

Studies

The one study Humanis Saglık Anonim Sirketi leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07266792Schizophrenia · India1CompletedAug 4, 202536

How it is read

Names in the registry

  • “Brexpiprazole”, 44 entries
  • “OPC-34712”, 17 entries
  • “Brexpiprazole (OPC-34712)”, 2 entries
  • “Brexpiprazole, OPC-34712”, 2 entries
  • “OPC-34712 + ADT”, 2 entries

Codes read as this program: OPDC34712.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.